Filippatos T D, Elisaf M S
a Department of Internal Medicine, School of Medicine , University of Ioannina , Ioannina , Greece.
Expert Rev Clin Pharmacol. 2016 Jul;9(7):955-60. doi: 10.1586/17512433.2016.1165607. Epub 2016 Mar 28.
Statins are the cornerstone of hypolipidemic treatment but recently have been associated with increased risk of developing diabetes mellitus. However, the risk of incident diabetes is not the same among statins. Pitavastatin lowers low-density lipoprotein cholesterol and increases high-density lipoprotein cholesterol but also seems to be neutral in terms of risk of incident diabetes. Clinical and experimental evidence shows that pitavastatin increases adiponectin levels and reduces oxidative stress, effects that seem to be implicated in the beneficial effect of the drug on carbohydrate metabolism variables. Pitavastatin is a useful hypolipidemic drug, which is promising for patients with increased diabetes risk or established diabetes.
他汀类药物是降脂治疗的基石，但最近已被发现与患糖尿病风险增加有关。然而，不同他汀类药物引发糖尿病的风险并不相同。匹伐他汀可降低低密度脂蛋白胆固醇并升高高密度脂蛋白胆固醇，而且在引发糖尿病风险方面似乎呈中性。临床和实验证据表明，匹伐他汀可提高脂联素水平并减轻氧化应激，这些作用似乎与该药物对碳水化合物代谢变量的有益作用有关。匹伐他汀是一种有用的降脂药物，对于糖尿病风险增加或已确诊糖尿病的患者很有前景。
